Horizon Wealth Management LLC cut its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 96.8% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,734 shares of the financial services provider’s stock after selling 52,923 shares during the period. Horizon Wealth Management LLC’s holdings in iShares Biotechnology ETF were worth $293,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Basepoint Wealth LLC bought a new position in iShares Biotechnology ETF in the fourth quarter worth approximately $26,000. Cary Street Partners Financial LLC bought a new stake in iShares Biotechnology ETF during the 4th quarter valued at approximately $29,000. Darwin Wealth Management LLC purchased a new position in shares of iShares Biotechnology ETF in the second quarter worth $25,000. Caitlin John LLC bought a new position in shares of iShares Biotechnology ETF during the fourth quarter worth $34,000. Finally, Cornerstone Planning Group LLC bought a new position in shares of iShares Biotechnology ETF during the 4th quarter valued at about $35,000. Hedge funds and other institutional investors own 62.45% of the company’s stock.
iShares Biotechnology ETF Stock Performance
NASDAQ IBB opened at $190.12 on Thursday. iShares Biotechnology ETF has a 1-year low of $127.11 and a 1-year high of $191.15. The business has a 50 day simple moving average of $172.32 and a two-hundred day simple moving average of $171.49.
iShares Biotechnology ETF Cuts Dividend
iShares Biotechnology ETF Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Recommended Stories
- Five stocks we like better than iShares Biotechnology ETF
- AirJoule Unveils Prime System, Clearing Path to Commercialization
- Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks
- Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets
- Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
